Gain insights into how emerging treatments are reshaping the outcome for patients with ER+ breast cancer. Dr Stephen Luen will discuss some of the data behind emerging therapies and therapeutic strategies that are making their way into the clinic for treatment of estrogen receptor-positive breast cancer (ER+) breast cancer.
Dr Li is a medical oncologist with a strong interest in breast cancer, clinical trials and access to equitable healthcare. She is a recipient of the 2025 Breast Cancer Trials Clinical Fellowship, which will fund her research into identifying mechanisms and biomarkers of resistance to antibody-drug conjugates in the treatment of metastatic breast cancer.
Dr Luen is an early career medical oncologist and translational researcher specialising in breast cancer, sarcoma, early drug development, and precision oncology. In 2021, he completed a PhD supervised by Professor Sherene Loi investigating genomic and immune biomarkers in early-stage breast cancers, and continues to work closely with the laboratory. His current research interests include the development of novel clinical trial approaches for high-risk breast cancers, the early phase development of new therapeutic compounds, and the study of genomic and immune biomarkers in high-risk and treatment-refractory breast cancers.
